A daunting task: Manipulating leukocyte function with RNAi

Immunological Reviews

Volumn 253, Issue 1, 2013, Pages 185-197

  Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Integrins; Leukocytes; Liposomes; Nanoparticles; RNAi

Indexed keywords

APTAMER; ATELOCOLLAGEN; BETA7 INTEGRIN; CD18 ANTIGEN; CD7 ANTIGEN; CHOLINERGIC RECEPTOR; CLAUDIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; DNA; DOUBLE STRANDED RNA; EFALIZUMAB; GAMMA INTERFERON; GLYCOPROTEIN GP 160; HISTONE ACETYLTRANSFERASE; HYALURONIC ACID; INTEGRIN; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; NATALIZUMAB; OCCLUDIN; PROTAMINE; RNA; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS ANTIBODY;

CELL CYCLE; CELL INTERACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA REPAIR; ENTERITIS; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; LEUKOCYTE FUNCTION; MACROPHAGE; MELANOMA CELL; NANOENCAPSULATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; TUMOR GROWTH;

ANIMALS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; IMMUNOMODULATION; LEUKOCYTES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84875801524     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12044     Document Type: Review

References (124)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
2. Amarzguioui M, Rossi JJ, Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 2005;579:5974-5981.
3. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006;126:231-235.
4. Sledz CA, Williams BR. RNA interference in biology and disease. Blood 2005;106:787-794.
5. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-453.
6. Peer D, Lieberman J. Special delivery: targeted therapy with small RNAs. Gene Ther 2011;18:1127-1133.
7. Song E, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-717.
8. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319:627-630.
9. Palliser D, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006;439:89-94.
10. Song E, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.
11. Robbins M, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008;19:991-999.
12. Kleinman ME, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591-597.
13. Weinstein S, et al. RNA inhibition highlights cyclin d1 as a potential therapeutic target for mantle cell lymphoma. PLoS ONE 2012;7:e43343.
14. Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 2012;64:1508-1521.
15. Zimmermann TS, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-114.
16. Dorn G, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004;32:e49.
17. Shen J, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13:225-234.
18. Filleur S, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003;63:3919-3922.
19. Gaudilliere B, Shi Y, Bonni A. RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival. J Biol Chem 2002;277:46442-46446.
20. Miller VM, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003;100:7195-7200.
21. Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 2005;25:10502-10509.
22. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711-719.
23. Bramsen JB, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009;37:2867-2881.
24. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009;19:89-102.
25. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-319.
26. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006;13:541-552.
27. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-184.
28. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006;13:644-670.
29. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 2005;56:401-423.
30. Goldsmith M, Mizrahy S, Peer D. Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine 2011;6:1771-1785.
31. Goffinet C, Keppler OT. Efficient nonviral gene delivery into primary lymphocytes from rats and mice. FASEB J 2006;20:500-502.
32. Huang Z, King MR. An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation. Gene Ther 2009;16:1271-1282.
33. Eguchi A, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009;27:567-571.
34. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008;16:1481-1489.
35. Zhou J, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009;37:3094-3109.
36. Kortylewski M, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009;27:925-932.
37. Ishimoto T, et al. Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol Ther 2008;16:387-395.
38. Kumar P, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577-586.
39. Subramanya S, et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol 2010;84:2490-2501.
40. Kim SS, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 2010;18:993-1001.
41. Kumar P, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39-43.
42. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007;104:4095-4100.
43. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-434.
44. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687.
45. Lebwohl M, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-2013.
46. Sandborn WJ, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925.
47. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2:703-716.
48. Shimaoka M, et al. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 2003;112:99-111.
49. Peer D. Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. J Control Rel 2010;148:63-68.
50. Fabbri M, et al. Dynamic partitioning into lipid rafts controls the endo-exocytic cycle of the alphaL/beta2 integrin, LFA-1, during leukocyte chemotaxis. Mol Biol Cell 2005;16:5793-5803.
51. Coffey GP, et al. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004;310:896-904.
52. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314.
53. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
54. Shimaoka M, Takagi J, Springer TA. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct 2002;31:485-516.
55. Shimaoka M, et al. AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc Natl Acad Sci USA 2006;103:13991-13996.
56. Ben-Arie N, Kedmi R, Peer D. Integrin-targeted nanoparticles for siRNA delivery. Methods Mol Biol 2012;757:497-507.
57. Kim SS, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010;18:370-376.
58. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 2010;31:6867-6875.
59. Peer D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv Drug Deliv Rev 2012;64:1738-1748.
60. Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J Control Rel 2012;161:600-608.
61. Peer D, Florentin A, Margalit R. Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta 2003;1612:76-82.
62. Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 2004;108:780-789.
63. Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004;6:343-353.
64. Mizrahy S, Peer D. Polysaccharides as building blocks for nanotherapeutics. Chem Soc Rev 2012;41:2623-2640.
65. Mizrahy S, et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Rel 2011;156:231-238.
66. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003;15:158-163.
67. Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 2006;5:2110-2114.
68. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006;25:1620-1628.
69. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-5447.
70. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007;98:629-635.
71. Kozar K, Sicinski P. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle 2005;4:388-391.
72. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005;16:601-607.
73. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-4224.
74. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-762.
75. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
76. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
77. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-112.
78. Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23:6364-6369.
79. Kim SS, Subramanya S, Peer D, Shimaoka M, Shankar P. Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol Biol 2011;721:339-353.
80. Szoka F. Molecular biology. The art of assembly. Science 2008;319:578-579.
81. Maclachlan I. siRNAs with guts. Nat Biotechnol 2008;26:403-405.
82. Bachar G, et al. Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials 2011;32:4840-4848.
83. Landesman-Milo D, et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 2012. doi: 10.1016/j.canlet.2012.08.024.
84. Agrawal S, Kandimalla ER. Antisense and siRNA as agonists of Toll-like receptors. Nat Biotechnol 2004;22:1533-1537.
85. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004;172:6545-6549.
86. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-839.
87. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-462.
88. Hornung V, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-270.
89. Forsbach A, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008;180:3729-3738.
90. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005;348:1079-1090.
91. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther 2006;14:463-470.
92. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 2007;15:1663-1669.
93. Puthenveetil S, Whitby L, Ren J, Kelnar K, Krebs JF, Beal PA. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucl Acids Res 2006;34:4900-4911.
94. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006;13:494-505.
95. Morrissey DV, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-1007.
96. Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 2010;267:44-53.
97. Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2007;6:785-796.
98. Buyens K, et al. Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. J Control Rel 2012;158:362-370.
99. Shirazi RS, Ewert KK, Leal C, Majzoub RN, Bouxsein NF, Safinya CR. Synthesis and characterization of degradable multivalent cationic lipids with disulfide-bond spacers for gene delivery. Biochim Biophys Acta 2011;1808:2156-2166.
100. Akinc A, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26:561-569.
101. Nakanishi T, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 1997;240:793-797.
102. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD Jr, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 2006;23:385-395.
103. Chen Y, Bathula SR, Li J, Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010;285:22639-22650.
104. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004;43:13348-13356.
105. Solmesky LJ, Shuman M, Goldsmith M, Weil M, Peer D. Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. Nanotechnology 2011;22:494016.
106. Lonez C, Vandenbranden M, Ruysschaert JM. Cationic liposomal lipids: from gene carriers to cell signaling. Prog Lipid Res 2008;47:340-347.
107. Harel-Adar T, Ben Mordechai T, Amsalem Y, Feinberg MS, Leor J, Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci USA 2011;108:1827-1832.
108. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29-36.
109. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268:235-237.
110. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Rel 2003;88:35-42.
111. Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 2003;255:167-174.
112. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Rel 2007;122:349-355.
113. Gutman D, Epstein-Barash H, Tsuriel M, Golomb G. Alendronate liposomes for antitumor therapy: activation of gammadelta T Cells and inhibition of tumor growth. Adv Exp Med Biol 2012;733:165-179.
114. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DF. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998;37:12875-12883.
115. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004;22:1903-1913.
116. Gray MJ, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 2008;100:109-120.
117. Halder J, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-4924.
118. Landen CN Jr, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-6918.
119. Merritt WM, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100:359-372.
120. Gewirtz AM. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 2007;117:3612-3614.
121. Tanaka T, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-3696.
122. Villares GJ, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 2008;68:9078-9086.
123. Moyano DF, et al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc 2012;134:3965-3967.
124. Salas A, Shimaoka M, Kogan AN, Harwood C, von Andrian UH, Springer TA. Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity 2004;20:393-406.